Krishna Institute of Medical Sciences Business Update

Krishna Institute of Medical Sciences Earnings Call Transcript: Key Takeaways

KIMS delivered strong revenue growth led by Kondapur's rapid ramp-up, despite temporary margin compression from new oncology programs.

Krishna Institute of Medical Sciences Other Announcement

KIMS's CARE Ratings monitoring report shows ₹1,311.81 crore of the ₹1,476.45 crore QIP proceeds utilised till Q2 FY27. No deviation from the stated objects was reported.

Krishna Institute of Medical Sciences Management Change

KIMS re-appointed Dr. Abhinay Bollineni as Director & CEO, Dr. Bhaskara Rao Bollineni as CMD, and Ms. Dandamudi Anitha as Whole-time Director. Terms start in 2027.

Execution

5 years

Krishna Institute of Medical Sciences Investor Presentation: Key Takeaways

Q2 FY27 total revenue Rs13,630 Mn (+41.3% YoY), EBITDA Rs2,789 Mn (20.5% margin), PAT Rs757 Mn (+5.1% YoY). Expansion via 700+ beds planned.

Krishna Institute of Medical Sciences Results Update

KIMS reported Q2 FY27 consolidated revenue of Rs 1,363 Crore, up 41.3% YoY, with PAT of Rs 76 Crore. EBITDA rose 34% YoY to Rs 279 Crore.

Krishna Institute of Medical Sciences Q2 FY27 Results: Net Profit ₹74.6 Cr, Up 3.6% YoY

Krishna Institute of Medical Sciences Ltd reported revenue from operations of ₹1,344 Cr (+39.9% YoY) and net profit of ₹74.6 Cr (+3.6% YoY) for Q2 FY27.

Key figure

Net profit ₹74.6 Cr · +3.6% YoY

Italian Edibles Business Update

Italian Edibles revised its project timeline again, pushing commercial production from January 2027 to April 2027. Construction delays stem from steel prices, supply chain disruption, weather and labour shortages.

Execution

Commercial production revised to April 2027 from January 2027

Bajaj Finserv Business Update

Bajaj Finserv disclosed October 2026 monthly premium and new business data for its unlisted insurance subsidiaries. The figures are provisional.

Bajaj Finance Business Update

Bajaj Finance submitted its Half Yearly Report for FY2026-27 covering the six months to 30 September 2026. The report shows 28% consolidated PAT growth to ₹12,447 crore and a planned ₹17,500 crore capital raise.

Cohance Lifesciences Business Update

Cohance Lifesciences disclosed that USFDA issued the Establishment Inspection Report for its Pashamylaram facility, classifying the inspection as Voluntary Action Indicated. The inspection is now concluded.

Religare Enterprises Business Update

Religare Finvest, a material subsidiary, resumed lending after RBI lifted its Corrective Action Plan. It disbursed its first Loan Against Property on 6 November 2026.

Purple Wave Infocom Business Update

Purple Wave signed a 5-year data integration agreement with BPCL for its Hygiair devices. The Rs 10 crore figure is indicative, not firm order value.

Execution

5 years